Earnings Releases·Nov 5, 2026, 4:07 PM ET

Caribou Biosciences — Third Quarter 2026 Earnings Summary

Revenue declined to $1.6 million from $2.2 million year-over-year, while GAAP net loss narrowed to $26.6 million ($0.25/share) from $27.5 million ($0.30/share) in the prior year period.
The Board approved a restructuring to discontinue clinical trials for vispa-cel and CB-011, citing a challenging financing environment for allogeneic CAR-T therapies.
Cash and marketable securities decreased to $94.8 million as of September 30, 2026, from $142.8 million at year-end 2025, as the company transitions to exploring strategic alternatives.
No timeline has been set for the completion of the strategic review, with no further updates expected unless the Board approves a course of action or disclosure is required.